Every 10-Q that Definitive Healthcare Corp. (DH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DH filings page.
Definitive Healthcare Corp. reported lower subscription-based revenue and a significantly larger loss for the six months ended June 30, 2026. Revenue was $111.1 million versus $119.9 million a year earlier, as subscription services fell to $106.4 million. The company posted a net loss of $199.8 million, driven largely by a non-cash $197.2 million goodwill impairment after sustained stock price declines, compared with a $164.4 million loss in the prior-year period.
Despite the loss, operating cash flow remained positive at $23.0 million, and cash and cash equivalents were $170.9 million with short-term investments of $12.7 million. Term loan debt totaled $161.9 million. The company reduced its Tax Receivable Agreement liability to $12.0 million and settled an acquisition earnout dispute for $7.5 million. It also executed a 2026 restructuring plan, incurring $1.1 million of severance-related charges, and impaired $0.2 million of lease right-of-use assets. Nasdaq notified the company on June 18, 2026 that its share price no longer met the $1.00 minimum bid requirement, starting a 180-day remediation period. Remaining performance obligations were $213.4 million, indicating contracted future revenue.
Definitive Healthcare Corp. reported a sharp net loss as it fully wrote off goodwill and faced softer demand. For the quarter ended March 31, 2026, revenue was $55.9 million, down from $59.2 million a year earlier, with subscription services contributing $53.6 million.
The company recorded a non‑cash goodwill impairment charge of $197.2 million, eliminating its remaining goodwill and driving a net loss of $192.4 million and a basic and diluted loss per share of $1.32. Operating cash flow remained positive at $11.6 million, and cash and cash equivalents totaled $157.6 million with short‑term investments of $20.4 million.
Management cited past sales execution challenges, macroeconomic pressure on smaller and life sciences customers, and elevated churn, which reduced the customer base to about 2,260 and Enterprise Customers to 495. The company also initiated a 2026 restructuring plan, cutting roughly 40 employees and recording $1.1 million in related charges to support margin improvement.
Definitive Healthcare Corp. reported Q3 2025 revenue of $60.0 million versus $62.7 million a year ago, with gross profit of $46.0 million. Loss from operations was $8.7 million. Net loss attributable to Definitive Healthcare narrowed to $14.8 million from $130.9 million in Q3 2024, which included a large impairment.
Year to date, revenue was $180.0 million and operating cash flow was $51.1 million. The company reduced its 2021 Term Loan principal to $168.4 million and had no borrowings on its $50.0 million revolver, with $49.7 million available after a standby letter of credit. Total assets were $755.5 million, including goodwill of $216.8 million following a $176.5 million non‑cash goodwill impairment recorded in Q1 2025. Deferred revenue was $92.0 million, and remaining performance obligations totaled $247.3 million. Class A shares outstanding were 103,011,649 as of September 30, 2025.